- Home
- FCT vs FENC Comparison
FCT vs FENC Comparison
Compare FCT & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCT
- FENC
- Stock Information
- Founded
- FCT 2004
- FENC 1996
- Country
- FCT United States
- FENC United States
- Employees
- FCT N/A
- FENC N/A
- Industry
- FCT Finance Companies
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FCT Finance
- FENC Health Care
- Exchange
- FCT Nasdaq
- FENC Nasdaq
- Market Cap
- FCT 265.0M
- FENC 225.4M
- IPO Year
- FCT N/A
- FENC 2001
- Fundamental
- Price
- FCT $9.99
- FENC $8.67
- Analyst Decision
- FCT
- FENC Strong Buy
- Analyst Count
- FCT 0
- FENC 2
- Target Price
- FCT N/A
- FENC $13.50
- AVG Volume (30 Days)
- FCT 106.8K
- FENC 54.7K
- Earning Date
- FCT 01-01-0001
- FENC 11-06-2025
- Dividend Yield
- FCT 11.29%
- FENC N/A
- EPS Growth
- FCT N/A
- FENC N/A
- EPS
- FCT N/A
- FENC N/A
- Revenue
- FCT N/A
- FENC $33,302,000.00
- Revenue This Year
- FCT N/A
- FENC $0.96
- Revenue Next Year
- FCT N/A
- FENC $51.71
- P/E Ratio
- FCT N/A
- FENC N/A
- Revenue Growth
- FCT N/A
- FENC N/A
- 52 Week Low
- FCT $9.45
- FENC $3.96
- 52 Week High
- FCT $10.42
- FENC $9.42
- Technical
- Relative Strength Index (RSI)
- FCT 41.36
- FENC 48.27
- Support Level
- FCT $10.05
- FENC $8.96
- Resistance Level
- FCT $10.15
- FENC $9.13
- Average True Range (ATR)
- FCT 0.08
- FENC 0.28
- MACD
- FCT -0.02
- FENC -0.02
- Stochastic Oscillator
- FCT 26.47
- FENC 17.88
About FCT First Trust Senior Floating Rate Income Fund II of Beneficial Interest
First Trust Senior Floating Rate Income Fund II is a United States-based diversified, closed-end management investment company. Its investment objective is to seek a high level of current income. As a secondary objective, it attempts to preserve capital. The fund invests in a portfolio of senior secured floating-rate corporate loans (Senior Loans) of companies from different industries, such as Insurance, Software, Health Care Providers and Services, Professional Services, Health Care Technology, IT Services, and others.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.